As of Mar 30
| +0.91 / +0.76%|
The 25 analysts offering 12-month price forecasts for Vertex Pharmaceuticals Inc have a median target of 131.00, with a high estimate of 200.00 and a low estimate of 85.00. The median estimate represents a +8.04% increase from the last price of 121.25.
The current consensus among 29 polled investment analysts is to Hold stock in Vertex Pharmaceuticals Inc. This rating has held steady since March, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.